Gedeon Richter Predicts Two-Year Wait To Refile Pegfilgrastim, But Teriparatide Is In The Wings

 
• By Dean Rudge

A timeline to refile, for a second time, its proposed biosimilar to Neulasta with the EMA and plans to launch its biosimilar to Eli Lilly’s Forsteo across the EU featured on Gedeon Richter’s full-year earnings call for 2018.

Dog
Gedeon Richter is forecasting a 2021 refiling date for pegfilgrastim in Europe. "It will take another two years, just like it did in the previous round," management said. • Source: Shutterstock

More from Biosimilars

More from Products